Amyotrophic Lateral Sclerosis – Analysis and Market Forecasts to 2019...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Disease Overview 8
3.1 Motor Neuron Disease 8
3.2 Etiology and Pathophysiology 9
3.2.1 Etiology 9
3.2.2 Common Hypotheses for the Pathogenesis of Amyotrophic Lateral Sclerosis 10
3.2.3 Therapeutic Strategies Based on Pathophysiology 12
3.2.4 Risk Factors 12
3.2.5 Quality of Life 13
3.2.6 Prognosis 13
3.3 Epidemiology 14
3.3.1 Prevalence 14
3.4 Symptoms 16
3.5 Diagnosis and Referral 16
3.5.1 Physical Examination 17
3.5.2 Diagnostic Tests 18
3.5.3 Emerging Diagnostic Tests 19
3.6 Treatment Guidelines 19
3.7 Disease Management 20
3.7.1 Pharmacological Treatment 20
3.7.2 Supportive Care 22
4 Competitive Assessment 24
4.1 Overview 24
4.2 Strategic Competitor Assessment 24
4.3 Product Profiles – Major Brands 25
4.3.1 Rilutek (riluzole) 25
5 Opportunity and Unmet Need 28
5.1 Overview 28
5.2 Low Awareness 29
5.3 Disease-Modifying Drugs 29
5.4 High Cost of Therapy 30
6 Pipeline Assessment 31
6.1 Overview 31
6.2 Strategic Pipeline Assessment 31
6.3 Pipeline by Phases of Development 32
6.3.1 Phase III Pipeline 32
6.3.2 Phase II/III Pipeline 33
6.3.3 Phase II Pipeline 33
6.3.4 Phase I/II Pipeline 33
6.3.5 Phase I Pipeline 34
6.3.6 Preclinical and Discovery Pipeline 34
6.3.7 Status Unknown 34
6.4 Pipeline by Mechanism of Action 35
6.5 Technology Trends Analytic Framework 37
6.6 Promising Drugs in Clinical Development 38
6.6.1 ALS-02 39
6.6.2 Radicut (edaravone) 41
7 Clinical Trials Mapping 43
7.1 Clinical Trials by Region/Country (US, 5EU and Japan) 43
7.2 Clinical Trials by Phase 43
7.3 Clinical Trials by Trial Status 44
7.4 Prominent Sponsors 44
8 Current and Future Players 46
8.1 Overview 46
8.2 Trends in Corporate Strategy 46
8.3 Company Profiles 47
8.3.1 Sanofi 47
8.3.2 Avicena 48
8.3.3 Biogen 49
8.3.4 Mitsubishi Tanabe Pharma 51
8.3.5 Other Companies in the Amyotrophic Lateral Sclerosis Therapeutics Market 52
9 Licensing and Partnership Deals 53
9.1 Key Deals and Alliances 53
10 Market Outlook 54
10.1 Seven Major Markets Overview 54
10.2 Regional Analysis 57
10.2.1 United States 57
10.2.2 France 58
10.2.3 Germany 59
10.2.4 Italy 59
10.2.5 Spain 60
10.2.6 United Kingdom 60
10.2.7 Japan 61
10.3 Key Events 61
10.4 Drivers and Barriers 62
10.4.1 Drivers for the Amyotrophic Lateral Sclerosis Market 62
10.4.2 Barriers for the Amyotrophic Lateral Sclerosis Market 63
11 Appendix 64
11.1 Bibliography 64
11.2 Abbreviations 68
11.3 Methodology 70
11.3.1 Coverage 70
11.3.2 Secondary Research 70
11.3.3 Forecasting 71
11.3.4 Expert Panel Validation 73
11.4 Physicians and Specialists Included in this Study 74
11.5 About GlobalData 75
11.6 Contact Us 75
11.7 Disclaimer 75